Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CODA 001

Drug Profile

CODA 001

Alternative Names: Antisense deoxynucleotide oligomer - OcuNexus Therapeutics; Antisense oligonucleotide compound - OcuNexus Therapeutics; CODA001; Nexagon

Latest Information Update: 26 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CoDa Therapeutics (NZ); CoDa Therapeutics Inc
  • Developer CoDa Therapeutics Inc; OcuNexus Therapeutics
  • Class Antisense oligonucleotides; Antiulcers
  • Mechanism of Action Gap junction modulators; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Corneal injuries
  • No development reported Diabetic foot ulcer; Leg ulcer; Wounds

Most Recent Events

  • 13 Sep 2019 OcuNexus Therapeutics plans the phase II EXPEDE trial in Corneal injuries (NEX-PED-005; NCT04081103)
  • 26 Aug 2019 Phase-III clinical trials in Corneal injuries in USA (Topical), prior to August 2019 (OcuNexus Therapeutics pipeline, August 2019)
  • 02 Oct 2018 Eyevance Pharmaceuticals plans a pivotal trial for Corneal injuries (persistent corneal epithelial defect), in first quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top